Generation Uranium【GEN】銘柄情報

Generation Uranium Inc (GEN) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

0.075

( 7.14% )

買値

0.07

売値

0.075

出来高

133,856

0.07 日の範囲 0.075

0.00 52 週間の範囲 0.00

時価総額

5.313M

前日終値

0.07

始値

0.07

時刻

1000

0.075

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

$ 108,937

発行済株式数

70,833,445

配当利回り

PER

-1.27

1 株当たり利益 (EPS)

-0.06

歳入

純利益

-1.46M

Generation Uranium Inc. engages in the exploration and development of mineral properties in Canada. The company explores for uranium, gold, and silver deposits. Its flagship project, the Yath project, is located in Thelon Basin in Nunavut, Canada. The company was formerly known as Generation Gold Co... Generation Uranium Inc. engages in the exploration and development of mineral properties in Canada. The company explores for uranium, gold, and silver deposits. Its flagship project, the Yath project, is located in Thelon Basin in Nunavut, Canada. The company was formerly known as Generation Gold Corp. and changed its name to Generation Uranium Inc. in January 2024. Generation Uranium Inc. was incorporated in 2018 and is headquartered in Vancouver, Canada. 詳細を表示

セクター

Energy

業界

Other Energy Sources

ウェブサイト

generationuranium.com

本社

Vancouver, Canada

設立

2026

Generation Uranium Inc is listed in the Energy sector of the トロントベンチャー取引所 with ticker GEN. The last closing price for Generation Uranium was $0.07. Over the last year, Generation Uranium shares have traded in a share price range of $ 0.00 to $ 0.00.

Generation Uranium currently has 70,833,445 shares in issue. The market capitalisation of Generation Uranium is $5.31 million. Generation Uranium has a price to earnings ratio (PE ratio) of -1.27.

Emerging Markets Report: Piece of Cake

ORLANDO, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Today’s featured company is a simple story. It’s a uranium...

Genmab Files IND for HuMax-TF-ADC

Company Announcement IND for HuMax(R)-TF-ADC submitted to FDA Genmab's first IND submission for antibody-drug conjugate (ADC) product...

Genentech and Biogen Idec Refused a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Company Announcement Genentech and Biogen Idec refused re-hearing in Arzerra patent infringement case COPENHAGEN, Denmark, July 15, 2013...

Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder

Company Announcement First Phase III study with subcutaneous formulation of ofatumumab Ofatumumab to be investigated in new autoimmune...

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody-Drug Conjugate Combining HuMax-TAC and PBD Warhe

Media Release Antibody-drug conjugate (ADC) to be developed for cancer Combines strength of HuMax(R)-TAC with next generation...

Teprotumumab Restarts Clinical Development in New Indication

Company Announcement Teprotumumab (RG1507) to be investigated for new indication River Vision Development Corporation to conduct...

Genmab Launches Sponsored Level 1 American Depositary Receipt (ADR) Program

Company Announcement Genmab establishes Sponsored Level 1 ADR program Genmab ADRs can be traded on US over-the-counter (OTC) market...

GSK and Genmab Announce Positive Top-Line Results From Pivotal Study of ARZERRA(R) (ofatumumab) Combined With Chlorambucil in P

Company Announcement Median 22.4 month progression free survival in patients treated with ofatumumab plus chlorambucil, an improvement of...

Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Company Announcement Genentech and Biogen Idec have filed for re-hearing in the United States COPENHAGEN, Denmark, May 17, 2013 (GLOBE...

Genmab Announces Financial Results for the First Quarter of 2013

COPENHAGEN, Denmark, May 7, 2013 (GLOBE NEWSWIRE) -- Interim Report First Quarter 2013 Arzerra(r) received approval in Japan Arzerra net...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

GEN - Frequently Asked Questions (FAQ)

What is the current Generation Uranium Inc share price?

The current share price of Generation Uranium Inc is $ 0.075

How many Generation Uranium Inc shares are in issue?

Generation Uranium Inc has 70,833,445 shares in issue

What is the market cap of Generation Uranium Inc?

The market capitalisation of Generation Uranium Inc is CAD 5.31M

What is the 1 year trading range for Generation Uranium Inc share price?

Generation Uranium Inc has traded in the range of $ 0.00 to $ 0.00 during the past year

What is the PE ratio of Generation Uranium Inc?

The price to earnings ratio of Generation Uranium Inc is -1.27

What is the registered address of Generation Uranium Inc?

The registered address for Generation Uranium Inc is 2600 – 1066 West Hastings Street, Vancouver, British Columbia, V6E 3X1

What is the Generation Uranium Inc website address?

The website address for Generation Uranium Inc is generationuranium.com

Which industry sector does Generation Uranium Inc operate in?

Generation Uranium Inc operates in the Other Energy Sources sector

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Generation Uranium Inc (GEN)

Generation Uranium Inc (GEN) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

Generation Uranium Inc について

GEN 最新ニュース

Emerging Markets Report: Piece of Cake

Genmab Files IND for HuMax-TF-ADC

Genentech and Biogen Idec Refused a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody-Drug Conjugate Combining HuMax-TAC and PBD Warhe

Teprotumumab Restarts Clinical Development in New Indication

Genmab Launches Sponsored Level 1 American Depositary Receipt (ADR) Program

GSK and Genmab Announce Positive Top-Line Results From Pivotal Study of ARZERRA(R) (ofatumumab) Combined With Chlorambucil in P

Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Genmab Announces Financial Results for the First Quarter of 2013

GEN - Frequently Asked Questions (FAQ)

GEN 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Generation Uranium Inc (GEN)

Generation Uranium Inc (GEN) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

Generation Uranium Inc について

GEN 最新ニュース

Emerging Markets Report: Piece of Cake

Genmab Files IND for HuMax-TF-ADC

Genentech and Biogen Idec Refused a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody-Drug Conjugate Combining HuMax-TAC and PBD Warhe

Teprotumumab Restarts Clinical Development in New Indication

Genmab Launches Sponsored Level 1 American Depositary Receipt (ADR) Program

GSK and Genmab Announce Positive Top-Line Results From Pivotal Study of ARZERRA(R) (ofatumumab) Combined With Chlorambucil in P

Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Genmab Announces Financial Results for the First Quarter of 2013

GEN - Frequently Asked Questions (FAQ)

GEN 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS